drugset
drugset / Trial / NCT00042679

A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.

NCT00042679 ↗

Phase 2 Completed Eli Lilly and Company
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purposes of this study are to determine the following: Whether LY900003 plus gemcitabine and carboplatin can make your tumor smaller or disappear, and for how long. If treatment with LY900003 plus gemcitabine and carboplatin can help you live longer. The safety of LY900003 plus gemcitabine and carboplatin and any side effects that might be associated with the combination of these three drugs. How LY900003 is distributed and broken down by your body when it is given with carboplatin and gemcitabine. Whether LY900003 affects the way gemcitabine and carboplatin are distributed and broken down by your body.

Timeline

Start
2002-06
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject APRINOCARSEN Antisense oligonucleotide 2 mg/kg —
Subject Carboplatin Small molecule — —
Subject Gemcitabine Small molecule 1250 mg/m2 —

Indications

non-small cell lung carcinoma